Evogene Ltd. (NASDAQ:EVGN) Short Interest Update

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 23,600 shares, a decrease of 16.0% from the March 15th total of 28,100 shares. Based on an average daily volume of 24,400 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.5% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. StockNews.com assumed coverage on shares of Evogene in a research note on Saturday. They issued a “sell” rating on the stock. Alliance Global Partners reissued a “buy” rating on shares of Evogene in a research report on Friday, March 7th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Jane Street Group LLC purchased a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned 0.40% of Evogene at the end of the most recent reporting period. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Stock Down 11.0 %

NASDAQ:EVGN traded down $0.14 on Tuesday, reaching $1.13. 528,808 shares of the company’s stock were exchanged, compared to its average volume of 301,724. Evogene has a 52-week low of $0.95 and a 52-week high of $9.00. The business has a fifty day moving average of $1.30 and a 200-day moving average of $1.63. The firm has a market capitalization of $6.06 million, a price-to-earnings ratio of -0.25 and a beta of 1.37.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.78. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. The company had revenue of $1.61 million for the quarter, compared to analyst estimates of $3.63 million. During the same quarter last year, the company earned ($1.30) EPS.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.